IDEXX Laboratories Announces Third Quarter Results
▪ Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic.
Double-digit organic revenue growth was led by strong volume expansion, ▪ including benefits from IDEXX's innovations and excellent commercial execution.
▪ Places over 1,900 IDEXX inVue Dx™ analyzers during the quarter, driving installed base to nearly 11,000 instruments.
Delivers EPS of $4.01, an increase of 18% as reported and 22% on a ▪ comparable basis, with operating margin up 100 basis points as reported and 60 basis points on a comparable basis.
Increases 2026 revenue guidance to $4,741 million - $4,767 million, up ▪ $32 million at midpoint, reflecting strong CAG Diagnostics recurring revenue performance.
Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG ▪ Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%, with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth of 10.3% - 11.0%.
Raises 2026 EPS outlook to $14.96 - $15.16, reflecting a $0.25 increase ▪ compared to prior guidance midpoint, led by a raised revenue outlook while supporting acquisition impacts.
WESTBROOK, Maine, November 2, 2026 — IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced third quarter results.
The Company reports revenues of $1,214 million for the third quarter of 2026, an increase of 10% as reported and organic, driven by Companion Animal Group ("CAG") growth of 10% as reported and organic.
Third quarter earnings per diluted share (“EPS”) were $4.01, an increase of 18% as reported and 22% on a comparable basis. Third quarter EPS included $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share in tax benefits from share-based compensation, and $0.04 per share benefit from year-over-year currency changes, while absorbing acquisition impacts.
“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy,” said Mike Erickson, President and Chief Executive Officer. “Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently. In software, we advanced our capabilities with the acquisition of CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization, creating more value for our customers and shareholders."
CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 11% as reported and organic, including 13% reported and 14% organic gains in International regions and 10% reported and organic growth in the U.S., outpacing sector growth levels.
Additional U.S. companion animal practice key metrics are available in the Q3 2026 Earnings Snapshot accessible on the IDEXX website, .
Strong same-store volume growth, IDEXX innovation benefits, net customer gains and premium instrument installed base expansion drove double- digit CAG Diagnostics recurring revenue growth.
IDEXX VetLab™ consumables revenues grew 14% reported and 15% organic, ▪ supported by net new customer growth, including 11% expansion of the IDEXX global premium instrument installed base, utilization expansion with benefits from recent product launches and net price gains.
Reference laboratory diagnostic and consulting services generated 10% ▪ reported and organic revenue growth, driven by testing volume growth, net new customer gains, and price realization.
▪ Rapid assay products revenues increased 1% as reported and on an organic basis, driven by net price benefits, offsetting lower testing volumes.
CAG Diagnostics capital instrument revenues were flat on an as reported and an organic basis, with benefits from over 1,900 IDEXX inVue Dx placements during the quarter.
Veterinary software, services and diagnostic imaging systems revenues grew 11% on a reported and 10% on an organic basis for the quarter, with benefits from a strong quarter of diagnostic imaging systems installations, led by ImageVue DR50 Plus.
Water revenues grew 8% as reported and organic for the quarter, driven by growth in North America.
LPD revenues increased 3% as reported and organic for the quarter, led by growth in the Americas.
Gross profit increased 12% as reported and 12% on a comparable basis. Gross margin of 62.9% increased 110 basis points as reported and 90 basis points on a comparable basis, supported by strong recurring revenue volume gains, operational productivity initiatives, and net price realization.
Operating margin was 33.1% for the quarter, higher than the prior year period by 100 basis points as reported and by 60 basis points on a comparable basis. Operating margin results reflect a 10% operating expense increase as reported and 11% growth on a comparable basis. Operating expense growth supported expansion of IDEXX's commercial capabilities and advancement of the Company's innovation agenda, while absorbing acquisition impacts, including transaction-related costs.
The Company is updating its full year revenue growth guidance range to $4,741 million - $4,767 million, or reported growth of 10.1% - 10.8%, an increase of $32 million at midpoint, including $5 million related to the recent CoVet acquisition. The Company is increasing its outlook for organic revenue growth to 9.3% - 10.0%, an increase of 0.6% at midpoint, reflecting operational performance.
The Company lowered its full year reported operating margin outlook to 32.1% - 32.3%, bringing the projected full year operating profit margin expansion to 50 - 70 basis points as reported and on a comparable basis. The updated guidance includes acquisition-related impacts.
The Company updated its EPS outlook range to $14.96 - $15.16, a $0.25 increase compared to prior guidance midpoint, reflecting 15% reported and 16% comparable growth.
The following table provides the Company's updated outlook for annual key financial metrics in 2026 with a comparison to the prior outlook:
2026 Growth and Financial Performance Updated Prior Outlook Revenue $4,741 - $4,767 $4,700 - $4,745 Reported growth 10.1% - 10.8% 9.1% - 10.3% Organic growth 9.3% - 10.0% 8.5% - 9.7% CAG Diagnostics Recurring Revenue Growth Reported growth 11.0% - 11.7% 10.1% - 11.3% Organic growth 10.3% - 11.0% 9.5% - 10.7% Operating Margin 32.1% - 32.3% 32.3% - 32.5% Operating margin expansion 50 bps - 70 bps 70 bps - 90 bps Comparable margin expansion 50 bps - 70 bps 70 bps - 90 bps EPS $14.96 - $15.16 $14.69 - $14.94 Reported growth 14% - 16% 12% - 14% Comparable growth 15% - 16% 13% - 15% Other Key Metrics Net interest expense ~$32 ~$35 Share-based compensation tax benefit ~$19 ~$19 Share-based compensation tax rate ~1.3% ~1.3% benefit Effective tax rate ~20.5% ~21.1% Share-based compensation EPS impact ~$0.24 ~$0.24 Reduction in average shares ~2% 1.5% - 2% outstanding Operating Cash Flow (% of Net Income) 110% - 120% 110% - 120% Free Cash Flow (% of Net Income) 95% - 100% 90% - 100% Capital Expenditures ~$160 ~$180
The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2026.
Estimated Foreign Currency Exchange Rate Impacts 2026 Revenue growth rate impact ~0.7% CAG Diagnostics recurring revenue growth rate ~0.7% impact Operating margin growth impact ~30 bps EPS impact ~$0.25 EPS growth impact ~2% Go-Forward Foreign Currency Exchange Rate 2026 Assumptions In U.S. dollars euro $1.12 British pound $1.32 Canadian dollar $0.70 Australian dollar $0.69 Relative to the U.S. dollar Japanese yen ¥160 Chinese renminbi ¥6.80 Brazilian real R$5.05
IDEXX Laboratories, Inc. will host a conference call today at 8:30 a.m. (ET) to discuss its third quarter 2026 results and management’s outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, . An archived edition of the webcast will be available after 1:00 p.m. (ET) via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 715328.
IDEXX Laboratories, Inc. will host an Investor and Analyst Session at VMX in Orlando, Florida on Monday, January 18th at 1:00 p.m. (ET), highlighting IDEXX's next point-of-care analyzer, IDEXX MultiCue Dx ™. On-site participation is limited and advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact [email protected]. A live webcast and accompanying slide presentations will be available at www.idexx.com/investors. An archived webcast replay of the event will be available approximately one hour following the eventvia the same link.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit .
This earnings release and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements are included above under "2026 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "can", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; projected net price realization; trends and other factors impacting the pet healthcare industry, including pet population demographics and U.S. clinical visits, and their anticipated effects on the Company; IDEXX inVue Dx analyzer placements; IDEXX Cancer Dx TMtesting panel expansion; CoVet acquisition-related impacts; and CoVet integration plans. These statements are intended to provide management's expectations or forecasts of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, our ability to successfully integrate CoVet, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in the corresponding sections of the Company's Quarterly Report on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non- GAAP financial measures may not be the same as similarly titled measures reported by other companies.
- Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimate the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted third quarter 2026 results as follows: increased gross profit growth by 0.2%, increased gross margin expansion 20 basis points, decreased operating expense growth by 0.9%, increased operating profit growth by 1.2%, increased operating profit margin growth by 40 basis points, and increased EPS growth by 1.2%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three and nine months ended September 30, 2026 and refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2026 projections and estimates.
- All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percentage change in revenue, as compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and nine months ended September 30, 2026. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2026 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to have an immaterial impact on projected full year 2026 revenue growth and no impact on CAG Diagnostics recurring revenue growth.
We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current period and the comparable prior year period to foreign currency denominated revenues for the prior year period.
We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.” We do not consider acquired assets to be a business if substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. A typical acquisition that we do not consider a business is a customer relationship asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. Revenue from these customers acquired is included in organic revenue growth because we believe the efforts required to convert and retain these acquired customers are similar in nature to our efforts to obtain and retain our existing customer base.
- Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.
Projected 2026 comparable operating margin expansion outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) full year 2026 reported operating margin adjusted for a $5 million unfavorable impact of loss on an equity investment; (ii) adjustment to projected 2026 operating margin for a positive impact from year-over-year foreign currency exchange rate changes at noted exchange rates; and (iii) adjustment to 2025 operating margin for the positive impact of the approximately $9 million discrete litigation expense accrual adjustment in the first quarter of 2025.
These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2026) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.
- Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, "Compensation-Stock Compensation (Topic 718): Improvements to Employee Share- Based Payment Accounting," and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.
Amounts presented may not recalculate due to rounding. Projected 2026 comparable EPS growth outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) adjustment to projected full year 2026 reported EPS for estimated positive year-over-year foreign currency exchange rate change impact of $0.25 at noted exchange rates; (ii) adjustment to projected full year 2026 reported EPS for estimated positive impact of share-based compensation activity of $0.24; (iii) adjustment to projected full year 2026 EPS of $0.05 for unfavorable impact of a loss on an equity investment; (iv) adjustment to full year 2025 reported EPS for a positive $0.08 impact from the discrete litigation expense accrual adjustment in the first quarter of 2025; and (v) adjustment to full year 2025 reported EPS for positive impact of share-based compensation activity of $0.35.
These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2026 reported EPS growth) to comparable EPS growth for the Company.
- We report segment income from operations in our Segment Information table below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, or superior measure to, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment’s operations.
The reconciliation of this non-GAAP financial measure is as follows for the three and nine months ended September 30, 2026 and 2025:
- Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three and nine months ended September 30, 2026 and 2025. To estimate projected 2026 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $160 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended September 30, 2026, we have deducted purchases of property and equipment of approximately $115 million from net cash provided from operating activities of approximately $1,419 million, divided by net income of approximately $1,182 million.
- During the first quarter of 2025, the Company reduced its previously established $89.0 million accrual related to a concluded litigation matter by approximately $9 million, which represented our best estimate at that time of the amount of the loss.
- The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the trial court on the same date, concluding this matter.
Amounts presented may not recalculate due to rounding. IDEXX Announces Third Quarter Results
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.
1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.
2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.
September September Nine Months 30, 30, Ended 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash Flows Operating: from Operating Activities: Net income $ 934,003 $ 811,276 Non-cash adjustments 198,224 259,262 to net income Changes in assets and (69,100 ) (244,493 ) liabilities Net cash provided by 1,063,127 826,045 operating activities Cash Flows Investing: from Investing Activities: Purchases of property (85,560 ) (95,242 ) and equipment Purchases of equity (1,695 ) (756 ) investments Proceeds from equity 4,111 — investments Acquisitio… (227,122 ) (13,350 ) Proceeds from net 3,126 1,239 investment hedges Net cash used by (307,140 ) (108,109 ) investing activities Cash Flows Financing: from Financing Activities: Borrowings under credit 76,000 205,000 facility, net Payments of senior (75,000 ) (103,386 ) notes Repurchases of common (810,014 ) (979,190 ) stock Proceeds from exercises of stock options and 82,551 75,493 employee stock purchase plans Shares withheld for statutory tax (11,003 ) (7,179 ) withholding payments on restricted stock Net cash used by (737,466 ) (809,262 ) financing activities Net effect of changes in exchange (1,055 ) 11,226 rates on cash Net increase (decrease) 17,466 (80,100 ) in cash and cash equivalents Cash and cash equivalent… 180,070 288,266 beginning of period Cash and cash equivalent… $ 197,536 $ 208,166 end of period
Full text with the tables
Exhibit 99.1
IDEXX Laboratories Announces Third Quarter Results
▪ Achieves third quarter revenue growth of 10% as reported and organic and
CAG Diagnostics recurring revenue growth of 11% as reported and organic.
Double-digit organic revenue growth was led by strong volume expansion,
▪ including benefits from IDEXX's innovations and excellent commercial
execution.
▪ Places over 1,900 IDEXX inVue Dx™ analyzers during the quarter, driving
installed base to nearly 11,000 instruments.
Delivers EPS of $4.01, an increase of 18% as reported and 22% on a
▪ comparable basis, with operating margin up 100 basis points as reported
and 60 basis points on a comparable basis.
Increases 2026 revenue guidance to $4,741 million - $4,767 million, up
▪ $32 million at midpoint, reflecting strong CAG Diagnostics recurring
revenue performance.
Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG
▪ Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%,
with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG
Diagnostics recurring revenue organic growth of 10.3% - 11.0%.
Raises 2026 EPS outlook to $14.96 - $15.16, reflecting a $0.25 increase
▪ compared to prior guidance midpoint, led by a raised revenue outlook
while supporting acquisition impacts.
WESTBROOK, Maine, November 2, 2026 — IDEXX Laboratories, Inc.
(Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced
third quarter results.
Third Quarter Results
The Company reports revenues of $1,214 million for the third quarter
of 2026, an increase of 10% as reported and organic, driven by Companion Animal
Group ("CAG") growth of 10% as reported and
organic.
Third quarter earnings per diluted share (“EPS”) were $4.01,
an increase of 18% as reported and 22% on a comparable basis. Third quarter EPS
included $0.03 per share benefit from a non-operating
gain on an equity investment, $0.01 per share in tax benefits from share-based
compensation, and $0.04 per share benefit from year-over-year
currency changes, while absorbing acquisition impacts.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 2 of 17
“IDEXX delivered exceptional third quarter results, reflecting
strong commercial execution and momentum from our innovation-driven growth
strategy,” said Mike Erickson, President and Chief Executive
Officer. “Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming
a multi-cancer panel, are helping practices detect
disease earlier and work more efficiently. In software, we advanced our
capabilities with the acquisition of CoVet, an AI clinical assistant
that supports veterinary team productivity and diagnostics utilization, creating
more value for our customers and shareholders."
Third Quarter Performance Highlights
Companion Animal Group (“CAG”)
CAG revenue growth was led by CAG Diagnostics recurring revenue growth
of 11% as reported and organic, including 13% reported and 14% organic gains in
International regions and 10% reported and organic growth
in the U.S., outpacing sector growth levels.
Additional U.S. companion animal practice key metrics are available
in the Q3 2026 Earnings Snapshot accessible on the IDEXX website, .
Strong same-store volume growth, IDEXX innovation benefits, net
customer gains and premium instrument installed base expansion drove double-
digit CAG Diagnostics recurring revenue growth.
IDEXX VetLab™ consumables revenues grew 14% reported and 15% organic,
▪ supported by net new customer growth, including 11% expansion of the
IDEXX global premium instrument installed base, utilization expansion
with benefits from recent product launches and net price gains.
Reference laboratory diagnostic and consulting services generated 10%
▪ reported and organic revenue growth, driven by testing volume growth, net
new customer gains, and price realization.
▪ Rapid assay products revenues increased 1% as reported and on an organic
basis, driven by net price benefits, offsetting lower testing volumes.
CAG Diagnostics capital instrument revenues were flat on an as reported
and an organic basis, with benefits from over 1,900 IDEXX inVue Dx placements
during the quarter.
Veterinary software, services and diagnostic imaging systems revenues
grew 11% on a reported and 10% on an organic basis for the quarter, with
benefits from a strong quarter of diagnostic imaging systems
installations, led by ImageVue DR50 Plus.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 3 of 17
Water
Water revenues grew 8% as reported and organic for the quarter, driven
by growth in North America.
Livestock, Poultry and Dairy (“LPD”)
LPD revenues increased 3% as reported and organic for the quarter,
led by growth in the Americas.
Gross Profit and Operating Profit
Gross profit increased 12% as reported and 12% on a comparable basis.
Gross margin of 62.9% increased 110 basis points as reported and 90 basis points
on a comparable basis, supported by strong recurring
revenue volume gains, operational productivity initiatives, and net price
realization.
Operating margin was 33.1% for the quarter, higher than the prior year
period by 100 basis points as reported and by 60 basis points on a comparable
basis. Operating margin results reflect a 10% operating
expense increase as reported and 11% growth on a comparable basis. Operating
expense growth supported expansion of IDEXX's commercial
capabilities and advancement of the Company's innovation agenda, while absorbing
acquisition impacts, including transaction-related costs.
2026 Growth and Financial Performance Outlook
The Company is updating its full year revenue growth guidance range
to $4,741 million - $4,767 million, or reported growth of 10.1% - 10.8%, an
increase of $32 million at midpoint, including $5 million
related to the recent CoVet acquisition. The Company is increasing its outlook
for organic revenue growth to 9.3% - 10.0%, an increase
of 0.6% at midpoint, reflecting operational performance.
The Company lowered its full year reported operating margin outlook
to 32.1% - 32.3%, bringing the projected full year operating profit margin
expansion to 50 - 70 basis points as reported and on a comparable
basis. The updated guidance includes acquisition-related impacts.
The Company updated its EPS outlook range to $14.96 - $15.16, a $0.25
increase compared to prior guidance midpoint, reflecting 15% reported and 16%
comparable growth.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 4 of 17
The following table provides the Company's updated outlook for annual
key financial metrics in 2026 with a comparison to the prior outlook:
Amounts in millions except per share data and percentages
2026 Growth and Financial Performance Updated Prior
Outlook
Revenue $4,741 - $4,767 $4,700 - $4,745
Reported growth 10.1% - 10.8% 9.1% - 10.3%
Organic growth 9.3% - 10.0% 8.5% - 9.7%
CAG Diagnostics Recurring Revenue
Growth
Reported growth 11.0% - 11.7% 10.1% - 11.3%
Organic growth 10.3% - 11.0% 9.5% - 10.7%
Operating Margin 32.1% - 32.3% 32.3% - 32.5%
Operating margin expansion 50 bps - 70 bps 70 bps - 90 bps
Comparable margin expansion 50 bps - 70 bps 70 bps - 90 bps
EPS $14.96 - $15.16 $14.69 - $14.94
Reported growth 14% - 16% 12% - 14%
Comparable growth 15% - 16% 13% - 15%
Other Key Metrics
Net interest expense ~$32 ~$35
Share-based compensation tax benefit ~$19 ~$19
Share-based compensation tax rate ~1.3% ~1.3%
benefit
Effective tax rate ~20.5% ~21.1%
Share-based compensation EPS impact ~$0.24 ~$0.24
Reduction in average shares ~2% 1.5% - 2%
outstanding
Operating Cash Flow (% of Net Income) 110% - 120% 110% - 120%
Free Cash Flow (% of Net Income) 95% - 100% 90% - 100%
Capital Expenditures ~$160 ~$180
IDEXX Announces Third Quarter Results
November 2, 2026
Page 5 of 17
The following table outlines estimates of foreign currency exchange
rate impacts, net of foreign currency hedging transactions, and foreign currency
exchange rate assumptions reflected in the above financial
performance outlook for 2026.
Estimated Foreign Currency Exchange Rate Impacts 2026
Revenue growth rate impact ~0.7%
CAG Diagnostics recurring revenue growth rate ~0.7%
impact
Operating margin growth impact ~30 bps
EPS impact ~$0.25
EPS growth impact ~2%
Go-Forward Foreign Currency Exchange Rate 2026
Assumptions
In U.S. dollars
euro $1.12
British pound $1.32
Canadian dollar $0.70
Australian dollar $0.69
Relative to the U.S. dollar
Japanese yen ¥160
Chinese renminbi ¥6.80
Brazilian real R$5.05
Conference Call and Webcast Information
IDEXX Laboratories, Inc. will host a conference call today at
8:30 a.m. (ET) to discuss its third quarter 2026 results and management’s
outlook. Individuals can access a live webcast of
the conference call through a link on the IDEXX website, . An archived edition
of the webcast will be available
after 1:00 p.m. (ET) via the same link and will remain available for one year.
The live call also will be accessible by telephone.
To listen to the live conference call, please dial 1-800-330-6730 or
1-213-279-1575 and reference passcode 715328.
2027 VMX Event
IDEXX Laboratories, Inc. will host an Investor and Analyst Session at VMX in
Orlando, Florida on Monday, January 18th at 1:00 p.m. (ET), highlighting IDEXX's
next point-of-care analyzer, IDEXX MultiCue Dx ™. On-site participation is
limited and advance registration for the in-person event is required;
institutional investors and analysts interested in attending should contact
[email protected]. A live webcast and accompanying slide presentations
will be available at www.idexx.com/investors. An archived webcast replay of the
event will be available approximately one hour following the eventvia the same
link.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 6 of 17
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic
and software products and services create clarity in the complex, constantly
evolving world of veterinary medicine. We support longer,
fuller lives for pets by delivering insights and solutions that help the
veterinary community around the world make confident decisions—to
advance medical care, improve efficiency, and build thriving practices. Our
innovations also help measure the safety of milk and water
across the world and maintain the health and well-being of people and livestock.
IDEXX Laboratories, Inc. is a member of the S&P
500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people
and offers solutions and products
to customers in more than 175 countries and territories. For more information
about IDEXX, visit .
Note Regarding Forward-Looking Statements
This earnings release and the statements to be made in the accompanying earnings
conference call contain forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, including statements about the
Company’s business prospects and estimates of the Company’s financial results
for future periods. Forward-looking statements are included above under "2026
Growth and Financial Performance Outlook" and elsewhere and can be identified by
the use of words such as "expects", "may", "can", "anticipates", "intends",
"would", "will", "plans", "believes", "estimates", "projected", "should", and
similar words and expressions. Our forward-looking statements include statements
relating to our expectations regarding financial performance; revenue growth and
EPS outlooks; operating and free cash flow forecast; projected impact of foreign
currency exchange rates and interest rates; projected operating margins and
expenses and capital expenditures; projected tax, tax rate and EPS benefits from
share-based compensation arrangements; projected effective tax rates, reduction
of average shares outstanding and net interest expense; projected net price
realization; trends and other factors impacting the pet healthcare industry,
including pet population demographics and U.S. clinical visits, and their
anticipated effects on the Company; IDEXX inVue Dx analyzer placements; IDEXX
Cancer Dx TMtesting panel expansion; CoVet acquisition-related impacts; and
CoVet integration plans. These statements are intended to provide management's
expectations or forecasts of future events as of the date of this earnings
release; are based on management's estimates, projections, beliefs, and
assumptions as of the date of this earnings release; and are not guarantees of
future performance. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the Company's actual results, levels of
activity, performance or achievements to be materially different from those
expressed or implied by these forward-looking statements. These risks and
uncertainties include, among other things, the adverse impact, and the duration,
of macroeconomic events, conditions, and uncertainties, such as geopolitical
instability (including wars, terrorist attacks, and armed conflicts), general
economic uncertainty, changes in U.S. and other countries’ tariff and trade
policies, severe weather and other natural conditions, our ability to
successfully integrate CoVet, and supply chain challenges on our business,
results of operations, liquidity, financial condition, and stock price, as well
as the matters described under the headings "Business," "Risk Factors," "Legal
Proceedings," "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and "Quantitative and Qualitative Disclosures About
Market Risk" in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2025 and in the corresponding sections of the Company's Quarterly
Report on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and
September 30, 2026, as well as those described from time to time in the
Company’s other filings with the U.S. Securities and Exchange Commission
available at www.sec.gov. The Company specifically disclaims any obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Statement Regarding Non-GAAP Financial Measures
The following defines terms and conventions and provides reconciliations
regarding certain measures used in this earnings release and/or the accompanying
earnings conference call that are not required by, or presented in accordance
with, generally accepted accounting principles in the United States of America
("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement
the Company’s consolidated results presented in accordance with GAAP, the
Company has disclosed non-GAAP financial measures that exclude or adjust certain
items. Management believes these non-GAAP financial measures provide useful
supplemental information for its and investors’ evaluation of the Company’s
business performance and liquidity and are useful for period-over-period
comparisons of the performance of the Company’s business and its liquidity and
to the performance and liquidity of our peers. While management believes that
these non-GAAP financial measures are useful in evaluating the Company’s
business, this information should be considered as supplemental in nature and
should not be considered in isolation or as a substitute for the related
financial information prepared in accordance with GAAP. In addition, these non-
GAAP financial measures may not be the same as similarly titled measures
reported by other companies.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 7 of 17
- Constant currency references are non-GAAP
financial measures which exclude the impact of changes in foreign currency
exchange rates and are consistent with how management evaluates
our performance and comparisons with prior and future periods. We estimate the
net impacts of currency on our revenue, gross profit, operating
profit, and EPS results by restating results to the average exchange rates or
exchange rate assumptions for the comparative period, which
includes adjusting for the estimated impacts of foreign currency hedging
transactions and certain impacts on our effective tax rates.
These estimated currency changes impacted third quarter 2026 results as follows:
increased gross profit growth by 0.2%, increased gross
margin expansion 20 basis points, decreased operating expense growth by 0.9%,
increased operating profit growth by 1.2%, increased operating
profit margin growth by 40 basis points, and increased EPS growth by 1.2%.
Constant currency revenue growth represents the percentage
change in revenue during the applicable period, as compared to the prior year
period, excluding the impact of changes in foreign currency
exchange rates. See the supplementary analysis of results below for revenue
percentage change from currency for the three and nine months
ended September 30, 2026 and refer to the 2026 Growth and Financial Performance
Outlook section of this earnings release for estimated
foreign currency exchange rate impacts on 2026 projections and estimates.
- All references to growth
and organic growth refer to growth compared to the equivalent prior year period
unless specifically noted. Organic revenue growth is a
non-GAAP financial measure that represents the percentage change in revenue, as
compared to the same period for the prior year, net of
the effect of changes in foreign currency exchange rates, certain business
acquisitions, and divestitures. Management believes that reporting
organic revenue growth provides useful information to investors by facilitating
easier comparisons of our revenue performance with prior
and future periods and to the performance of our peers. Organic revenue growth
should be considered in addition to, and not as a replacement
of or a superior measure to, revenue growth reported in accordance with GAAP.
See the supplementary analysis of results below for a reconciliation
of reported revenue growth to organic revenue growth for the three and nine
months ended September 30, 2026. Please refer to the
constant currency note above for a summary of foreign currency exchange rate
impacts. Please refer to the 2026 Growth and Financial Performance
Outlook section of this earnings release for estimated full year 2026 organic
revenue growth for the Company and CAG Diagnostics recurring
revenue growth. The percentage change in revenue resulting from acquisitions
represents revenues during the current year period, limited
to the initial 12 months from the date of the acquisition, that are directly
attributable to business acquisitions. Revenue from acquisitions
is expected to have an immaterial impact on projected full year 2026 revenue
growth and no impact on CAG Diagnostics recurring revenue
growth.
We exclude from organic revenue growth the effect of changes in foreign
currency exchange rates because changes in foreign currency exchange rates are
not under management’s control, are subject to volatility,
and can obscure underlying business trends. We calculate the impact on revenue
resulting from changes in foreign currency exchange rates
by applying the difference between the weighted average exchange rates during
the current period and the comparable prior year period
to foreign currency denominated revenues for the prior year period.
We also exclude from organic revenue growth the effect of certain business
acquisitions and divestitures because the nature, size, and number of these
transactions can vary dramatically from period to period,
and because they either require or generate cash as an inherent consequence of
the transaction, and therefore can also obscure underlying
business and operating trends. We consider acquisitions to be a business when
all three elements of inputs, processes, and outputs are
present, consistent with ASU 2017-01, “Business Combinations: (Topic 805)
Clarifying the Definition of a Business.”
We do not consider acquired assets to be a business if substantially all the
fair value of the assets acquired is concentrated in a single
identifiable asset or group of similar identifiable assets. A typical
acquisition that we do not consider a business is a customer relationship
asset acquisition, which does not have all elements necessary to operate a
business, such as employees or infrastructure. Revenue from
these customers acquired is included in organic revenue growth because we
believe the efforts required to convert and retain these acquired
customers are similar in nature to our efforts to obtain and retain our existing
customer base.
- Comparable gross profit growth,
comparable gross margin gain (or growth), comparable operating expense growth,
comparable operating profit growth and comparable operating
margin gain (or growth) are non-GAAP financial measures and exclude the impact
of changes in foreign currency exchange rates and non-recurring
or unusual items (if any). Please refer to the constant currency note above for
a summary of foreign currency exchange rate impacts. Management
believes that reporting comparable gross profit growth, comparable gross margin
gain (or growth), comparable operating expense growth,
comparable operating profit growth and comparable operating margin gain (or
growth) provides useful information to investors because it
enables better period-over-period comparisons of the fundamental financial
results by excluding items that vary independent of performance
and provides greater transparency to investors regarding key metrics used by
management. Comparable gross profit growth, comparable gross
margin gain (or growth), comparable operating expense growth, comparable
operating profit growth and comparable operating margin gain
(or growth) should be considered in addition to, and not as replacements of or
superior measures to, gross profit growth, gross margin
gain, operating expense growth, operating profit growth and operating margin
gain reported in accordance with GAAP.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 8 of 17
The reconciliation of these non-GAAP financial measures is as follows:
… T… N…
… M… M…
… E… S… S… … E… … … Y…
… 2… 3… 2… 3… … 2… … 2… … C…
──────────────────────────────────────────────────────────────────────────────
…
…
… $ 7… $ 6… 12 % $ … $ … … %
…
…
…
…
…
… 6… % 6… % 1… … … % … % … b…
…
…
…
…
…
…
… 1… — … —
…
…
…
… $ 7… $ 6… 12 % $ … $ … … %
…
…
…
…
… 6… % 6… % 90 … … % … % … b…
…
…
…
…
…
… $ 3… $ 3… 10 % $ … $ … … %
…
…
…
…
…
…
…
… (… ) — … —
…
…
… — — … —
…
…
…
… — — — … )
…
…
…
… $ 3… $ 3… 11 % $ … $ … … %
…
…
…
…
… $ 4… $ 3… 13 % $ … $ … … %
…
…
…
…
…
… 3… % 3… % 1… … … % … % … b…
…
…
…
…
…
…
… 4… — … —
…
…
… — — … ) —
…
…
…
… — — — …
…
…
…
… $ 3… $ 3… 12 % $ … $ … … %
…
…
…
…
… 3… % 3… % 60 … … % … % … b…
…
…
…
Amounts presented may not recalculate due to rounding.
Projected 2026 comparable operating margin expansion outlined in the
2026 Growth and Financial Performance Outlook section of this earnings release
reflects the following adjustments: (i) full year
2026 reported operating margin adjusted for a $5 million unfavorable impact of
loss on an equity investment; (ii) adjustment to projected
2026 operating margin for a positive impact from year-over-year foreign currency
exchange rate changes at noted exchange rates; and (iii) adjustment
to 2025 operating margin for the positive impact of the approximately $9 million
discrete litigation expense accrual adjustment in the
first quarter of 2025.
These impacts described above reconcile reported gross profit growth,
gross margin gain, operating expense growth, operating profit growth and
operating margin gain (including projected 2026) to comparable
gross profit growth, comparable gross margin gain, comparable operating expense
growth, comparable operating profit growth and comparable
operating margin gain for the Company.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 9 of 17
- Comparable EPS growth is a non-GAAP
financial measure that represents the percentage change in earnings per share
(diluted) ("EPS") for a measurement period, as
compared to the prior base period, net of the impact of changes in foreign
currency exchange rates from the prior base period and excluding
the tax benefits of share-based compensation activity under ASU 2016-09,
"Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-
Based Payment Accounting," and non-recurring or unusual items (if any).
Management believes comparable EPS
growth is a more useful way to measure the Company’s business performance than
EPS growth because it enables better period-over-period
comparisons of the fundamental financial results by excluding items that vary
independent of performance and provides greater transparency
to investors regarding a key metric used by management. Comparable EPS growth
should be considered in addition to, and not as a replacement
of or a superior measure to, EPS growth reported in accordance with GAAP. Please
refer to the constant currency note above for a summary
of foreign currency exchange rate impacts.
The reconciliation of this non-GAAP financial measure is as follows:
T… Ni…
M… Mo…
E… Se… Se… Y… En… S… S… Ye…
2… 30, 2… 30, G… 20… 3… 20… 3… Gr…
──────────────────────────────────────────────────────────────────────────────
E…
p…
s… $ 4.… $ 3.… 18 % $ 1… $ 9… 18 %
(…
a…
g…
L…
c…
a…
S…
c… 0.… 0.… 0… 0…
a…
L…
on — — (… ) —
e…
i…
N…
l… — — — 0…
m…
C…
f… 0.… — 0… —
c…
C…
E… $ 3.… $ 3.… 22 % $ 1… $ 9… 18 %
a…
g…
Amounts presented may not recalculate due to rounding.
Projected 2026 comparable EPS growth outlined in the 2026 Growth and
Financial Performance Outlook section of this earnings release reflects the
following adjustments: (i) adjustment to projected full
year 2026 reported EPS for estimated positive year-over-year foreign currency
exchange rate change impact of $0.25 at noted exchange rates;
(ii) adjustment to projected full year 2026 reported EPS for estimated positive
impact of share-based compensation activity of $0.24;
(iii) adjustment to projected full year 2026 EPS of $0.05 for unfavorable impact
of a loss on an equity investment; (iv) adjustment
to full year 2025 reported EPS for a positive $0.08 impact from the discrete
litigation expense accrual adjustment in the first quarter
of 2025; and (v) adjustment to full year 2025 reported EPS for positive impact
of share-based compensation activity of $0.35.
These impacts and those described in the constant currency note above
reconcile reported EPS growth (including projected 2026 reported EPS growth) to
comparable EPS growth for the Company.
- We report segment
income from operations in our Segment Information table below. Segment income
from operations is a non-GAAP financial measure that adjusts
for the impact of foreign currency transaction gains and losses and should be
considered in addition to, and not as a replacement for,
or superior measure to, income from operations. We exclude foreign currency
transaction gains and losses for each reportable segment (CAG,
Water, and LPD) from segment income from operations and report the full amount
of foreign currency transaction gains and losses in Other.
We believe that reporting segment income from operations provides supplemental
analysis to help investors further evaluate each reportable
segment’s business performance by excluding foreign currency transaction gains
and losses, which are centrally managed by our corporate
treasury function and which we do not consider relevant for assessing the
results of each reportable segment’s operations.
The reconciliation of this non-GAAP financial measure is as follows
for the three and nine months ended September 30, 2026 and 2025:
T…
M…
E…
S… S… S…
3… a… a…
2… I… O… 2… I… O…
… I… f… I… I… f… I…
… f… F… f… f… F… f…
… O… C… O… O… C… O…
──────────────────────────────────────────────────────────────────────────────
… $ 37… $ (7… ) $ 36… $ 32… $ 1,… $ 32…
… 29… (50 ) 29… 26… 104 26…
… 1,… (49 ) 1,… 364 107 471
… 560 812 1,… 1,… (1… ) (5… )
… $ 40… $ — $ 40… $ 35… $ — $ 35…
IDEXX Announces Third Quarter Results
November 2, 2026
Page 10 of 17
N…
M…
E…
S… S… S…
3… a… a…
2… I… O… 2… I… O…
… I… f… I… I… f… I…
… f… F… f… f… F… f…
… O… C… O… O… C… O…
──────────────────────────────────────────────────────────────────────────────
… $ 1,… $ (1… ) $ 1,… $ 96… $ 2,… $ 97…
… 83… (8 ) 83… 71… 183 71…
… 5,… (5 ) 5,… (98 ) 189 91
… 920 122 1,… 3,… (2… ) 358
… $ 1,… $ — $ 1,… $ 1,… $ — $ 1,…
- Free cash flow is a non-GAAP financial measure
and means, with respect to a measurement period, the cash generated from
operations during that period, reduced by the Company’s
investments in property and equipment. Management believes free cash flow is a
useful measure because it indicates the cash the operations
of the business are generating after appropriate reinvestment for recurring
investments in property and equipment that are required to
operate the business. Free cash flow should be considered in addition to, and
not as a replacement of or a superior measure to, net cash
provided by operating activities. See the supplementary analysis of results
below for our calculation of free cash flow for the three
and nine months ended September 30, 2026 and 2025. To estimate projected 2026
free cash flow, we have deducted projected purchases
of property and equipment (also referred to as capital expenditures) of
approximately $160 million. Free cash flow conversion, or the
net income to free cash flow ratio, is a non-GAAP financial measure that is
defined as free cash flow, with respect to a measurement period,
divided by net income for the same period. To calculate trailing twelve-month
net income to free cash flow ratio for the twelve months
ended September 30, 2026, we have deducted purchases of property and equipment
of approximately $115 million from net cash provided
from operating activities of approximately $1,419 million, divided by net income
of approximately $1,182 million.
Notes and Definitions
- During the first quarter
of 2025, the Company reduced its previously established $89.0 million accrual
related to a concluded litigation matter by approximately
$9 million, which represented our best estimate at that time of the amount of
the loss.
- The Company was a defendant in
a litigation matter involving an alleged breach of contract for underpayment of
royalty payments made from 2004 through 2017 under an
expired patent license agreement, and the trial court ruled in favor of the
plaintiff in 2020. Following appeals and in light of the appellate
court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment
of approximately $80 million, and the plaintiff
executed a satisfaction and release of judgment, which was filed with the trial
court on the same date, concluding this matter.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 11 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)
Thr… Ni…
Mon… Mo…
End… Sep… Sep… En… Sep… Sep…
2026 30, 20… 30, 20… 30, 20… 30,
──────────────────────────────────────────────────────────────────────────────
Re… Rev… $ 1,2… $ 1,1… $ 3,5… $ 3,2…
Ex… Cost
and of 449… 421… 1,3… 1,2…
In… rev…
Gro… 764… 683… 2,2… 2,0…
pro…
Sal…
and 169… 159… 516… 476…
mar…
Gen…
and 123… 105… 359… 296…
adm…
Res…
and 68,… 63,… 200… 184…
dev…
Tot…
ope… 361… 328… 1,0… 957…
exp…
Inc…
from 402… 354… 1,1… 1,0…
ope…
Non…
inc… (3,… ) (10… ) (18… ) (27… )
(ex…
net
Inc…
bef…
pro… 399… 344… 1,1… 1,0…
for
inc…
tax…
Pro…
for 82,… 70,… 237… 205…
inc…
tax…
Net
Net inc…
In… att… $ 317… $ 274… $ 934… $ 811…
to
sto…
Ear…
per $ 4.02 $ 3.43 $ 11.… $ 10.…
sha…
Bas…
Ear…
per $ 4.01 $ 3.40 $ 11.… $ 9.99
sha…
Dil…
Sha…
out… 78,… 80,… 79,… 80,…
Bas…
Sha…
out… 79,… 80,… 79,… 81,…
Dil…
ID…
La…
In…
and
Su…
Se…
Op…
In…
(U…
Thr… Ni…
Mon… Mo…
End… En…
Sep… Se… Se… Se…
30, 30, 30, 30,
2026 20… 20… 20…
Op… Gro… 62.9 % 61.8 % 63.4 % 62.3 %
Ra… pro…
(as Sal…
a mar…
pe… gen… 24.1 % 24.0 % 24.5 % 24.0 %
of and
re… adm…
exp…
Res…
and 5.7 % 5.7 % 5.6 % 5.7 %
dev…
exp…
Inc…
from 33.1 % 32.1 % 33.3 % 32.5 %
ope…
Amounts presented
may not recalculate due to rounding.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 12 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Segment and Other Information
Amounts in thousands (Unaudited)
Thr… Sep… Per… Sep… Per…
Mon… 30, of 30, of
End… 2026 Rev… 2025 Rev…
──────────────────────────────────────────────────────────────────────────────
Re… CAG $ 1,1… $ 1,0…
Wat… 58,… 54,…
LPD 34,… 33,…
Oth… 4,6… 4,4…
Tot… $ 1,2… $ 1,1…
Gr… CAG $ 701… 62.8 % $ 627… 62.0 %
Pr…
Wat… 42,… 72.6 % 38,… 70.1 %
LPD 18,… 52.6 % 15,… 47.0 %
Oth… 1,9… 41.9 % 1,8… 42.5 %
Tot… $ 764… 62.9 % $ 683… 61.8 %
In…
fr… CAG $ 369… 33.1 % $ 328… 32.4 %
Op…
Wat… 29,… 50.3 % 26,… 48.6 %
LPD 1,8… 5.5 % 471 1.4 %
Oth… 1,3… 29.8 % (511 ) (11… )%
Tot… $ 402… 33.1 % $ 354… 32.1 %
Nine
Mon…
End…
Sep… Per… Sep… Pe…
30, of 30, of
2026 Rev… 2025 Re…
Re… CAG $ 3,2… $ 2,9…
Wat… 167… 150…
LPD 102… 94,…
Oth… 13,… 13,…
Tot… $ 3,5… $ 3,2…
Gr… CAG $ 2,0… 63.4 % $ 1,8… 62.4 %
Pr…
Wat… 122… 73.3 % 105… 70.1 %
LPD 53,… 52.6 % 45,… 48.0 %
Oth… 4,7… 36.0 % 6,2… 46.3 %
Tot… $ 2,2… 63.4 % $ 2,0… 62.3 %
In…
fr… CAG $ 1,1… 33.5 % $ 972… 32.9 %
Op…
Wat… 83,… 49.8 % 71,… 47.7 %
LPD 5,6… 5.5 % 91 0.1 %
Oth… 1,0… 7.9 % 358 2.7 %
Tot… $ 1,1… 33.3 % $ 1,0… 32.5 %
IDEXX Announces Third Quarter Results
November 2, 2026
Page 13 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by
Domestic and International Markets
Amounts in thousands (Unaudited)
P… …
… S… S… R… C… … …
… … 3… 3… D… R… f… … …
… … 2… 2… C… G… C… … …
──────────────────────────────────────────────────────────────────────────────
$ 1… $ 1… $ 1… 1… % (… … … % … %
7… 6… 5… 8… % — … % … %
3… 3… 4… 1… % (… … — … %
$ 5… $ 5… $ 4… 8… % 0… % — … %
3… 2… 3… 1… % — — … %
2… 2… 1… 5… % 1… % — … %
$ 3… $ 3… $ 8… 2… % (… … — … %
7… 6… 7… 1… % — — … %
2… 2… 94 0… % (… … — … %
$ 4… $ 4… $ 1… 3… % — — … %
$ 1… $ 1… $ 1… 9… % (… … … % … %
7… 7… 6… 8… % — … % … %
4… 4… 4… 1… % (… … — … %
…
…
…
… … … … P… O…
… … … … … C… R…
… … … … … f… G…
… A…
$ 9… $ 8… $ 9… 1… % (… … — … %
4… 3… 5… 1… % (… … — … %
8… 8… 4… 0… % (… … — … %
3… 3… 3… 1… % (… … — … %
3… 3… 1… 5… % (… … — … %
$ 5… $ 5… $ 13 — (… … — … %
$ 9… $ 8… $ 9… 1… % 0… % … % … %
7… 7… 6… 9… % 0… % … % … %
1… 1… 2… 1… % — — … %
$ 1… $ 1… $ 1… 1… % (… … … % … %
…
…
…
… … … … P… O…
… … … … … C… R…
… … … … … f… G…
… A…
$ 9… $ 8… $ 9… 1… % (… … — … %
6… 5… 5… 9… % — — … %
3… 3… 3… 1… % (… … — … %
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented
may not recalculate due to rounding.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 14 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by
Domestic and International Markets
Amounts in thousands (Unaudited)
P… P…
… … … … C… C… O…
… … … … … … f… f… R…
… … … … … … C… A… G…
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ … … % 1… % — 1… %
… … … … % — — 8… %
… … … … % 3… % — 1… %
$ … $ … $ … … % 2… % — 9… %
… … … … % — — 1… %
… … … … % 4… % — 6… %
$ … $ … $ … … % 2… % — 6… %
… … … … % — — 1… %
… … … … % 2… % — 5… %
$ … $ … $ … ) … )% — — (… …
$ … $ … $ … … % 1… % — 1… %
… … … … % — — 9… %
… … … … % 3… % — 1… %
…
…
…
… … … … … …
… … … … … … …
… … … … … … …
… …
$ … $ … $ … … % 1… % — 1… %
… … … … % 1… % — 1… %
… … … … % 0… % — 0… %
… … … … % 0… % — 1… %
… … … … % 1… % — 4… %
$ … $ … $ … ) … )% 0… % — (… …
$ … $ … $ … … % 0… % 0… % 1… %
… … … … % 0… % 0… % 9… %
… … … … % 0… % — 1… %
$ … $ … $ … … % 1… % — 1… %
…
…
…
… … … … … …
… … … … … … …
… … … … … … …
… …
$ … $ … $ … … % 1… % — 1… %
… … … … % — — 1… %
… … … … % 3… % — 1… %
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented
may not recalculate due to rounding.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 15 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet
Amounts in thousands (Unaudited)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
Assets: Current Assets:
Cash and cash $ 197,536 $ 180,070
equivalents
Accounts 615,799 552,378
receivable, net
Inventories 390,874 377,756
Other current 295,795 303,623
assets
Total current 1,500,004 1,413,827
assets
Property and 732,131 747,380
equipment, net
Other long-term 1,474,974 1,189,552
assets, net
Total assets $ 3,707,109 $ 3,350,759
Liabilities and
Stockholders'
Equity: Current
Liabilities:
Accounts payable $ 154,086 $ 110,408
Accrued 520,957 530,147
liabilities
Line of credit 474,000 398,000
Current portion 74,998 74,995
of long-term debt
Deferred revenue 40,181 35,264
Total current 1,264,222 1,148,814
liabilities
Long-term debt,
net of current 299,879 374,842
portion
Other long-term 273,831 221,720
liabilities, net
Total long-term 573,710 596,562
liabilities
Total
stockholders' 1,869,177 1,605,383
equity
Total liabilities
and stockholders' $ 3,707,109 $ 3,350,759
equity
IDEXX Laboratories, Inc. and Subsidiaries
Selected Balance Sheet Information (Unaudited)
Septe… June March Decem… Septem…
30, 30, 31, 31, 30,
2026 2026 2026 2025 2025
──────────────────────────────────────────────────────────────────────────────
Sele… Days
Bala… sales 46.7 46.2 46.2 46.8 46.5
Sheet outst…
Info…
Inven… 1.5 1.4 1.4 1.6 1.5
turns2
1Days sales outstanding represents the average of the accounts receivable
balances at the beginning and end of each quarter divided by revenue for that
quarter, the result of which is then multiplied by 91.25 days.
2Inventory turns are calculated as the ratio of our inventory-related cost of
revenue for the quarter multiplied by four, divided by the average inventory
balances at the beginning and end of each quarter.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 16 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)
September September
Nine Months 30, 30,
Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash Flows
Operating: from
Operating
Activities:
Net income $ 934,003 $ 811,276
Non-cash
adjustments 198,224 259,262
to net
income
Changes in
assets and (69,100 ) (244,493 )
liabilities
Net cash
provided by 1,063,127 826,045
operating
activities
Cash Flows
Investing: from
Investing
Activities:
Purchases
of property (85,560 ) (95,242 )
and
equipment
Purchases
of equity (1,695 ) (756 )
investments
Proceeds
from equity 4,111 —
investments
Acquisitio… (227,122 ) (13,350 )
Proceeds
from net 3,126 1,239
investment
hedges
Net cash
used by (307,140 ) (108,109 )
investing
activities
Cash Flows
Financing: from
Financing
Activities:
Borrowings
under
credit 76,000 205,000
facility,
net
Payments of
senior (75,000 ) (103,386 )
notes
Repurchases
of common (810,014 ) (979,190 )
stock
Proceeds
from
exercises
of stock
options and 82,551 75,493
employee
stock
purchase
plans
Shares
withheld
for
statutory
tax (11,003 ) (7,179 )
withholding
payments on
restricted
stock
Net cash
used by (737,466 ) (809,262 )
financing
activities
Net effect
of changes
in exchange (1,055 ) 11,226
rates on
cash
Net
increase
(decrease) 17,466 (80,100 )
in cash and
cash
equivalents
Cash and
cash
equivalent… 180,070 288,266
beginning
of period
Cash and
cash
equivalent… $ 197,536 $ 208,166
end of
period
IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow
Amounts in thousands (Unaudited)
Three Sep… Sept… Nine Sept… Sep…
Mont… 30, 30, Mon… 30, 30,
Ended 2026 2025 End… 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
Fr… cash
Ca… pro… $ 449… $ 402,… $ 1,06… $ 826…
Fl… by
ope…
act…
Inv…
cash
flo…
att…
to (28… ) (31,… ) (85,… ) (95… )
pur…
of
pro…
and
equ…
Free
cash $ 420… $ 371,… $ 977,… $ 730…
flo…
1See Statement Regarding Non-GAAP Financial Measures, above.
IDEXX Announces Third Quarter Results
November 2, 2026
Page 17 of 17
IDEXX Laboratories, Inc. and Subsidiaries
Common Stock Repurchases
Amounts in thousands except per share data (Unaudited)
Three Septem… Septem… Nine Septem… Septemb…
Months 30, 30, Months 30, 30,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Shares
repur…
in the 199 411 1,369 2,055
open
market
Shares
acqui…
throu…
emplo…
surre… — — 17 16
for
statu…
tax
withh…
Total
shares 199 411 1,386 2,071
repur…
Cost
of
shares
repur… $ 111,819 $ 241,568 $ 804,698 $ 978,313
in the
open
market
Cost
of
shares 150 85 11,003 7,179
for
emplo…
surre…
Total
cost $ 111,969 $ 241,653 $ 815,701 $ 985,492
of
shares
Avera…
cost
per
share $ 563.04 $ 587.50 $ 588.14 $ 475.92
– open
market
repur…
Avera…
cost
per
share $ 545.16 $ 647.08 $ 626.05 $ 454.46
–
emplo…
surre…
Avera…
cost
per $ 563.01 $ 587.52 $ 588.62 $ 475.76
share
–
total